Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex dose-ranging study for cancer pain
NCT00530764Phase 2Completed
- Sponsor
- GW Pharmaceuticals
- Start
- Nov 2007
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of cannabidiol in cancer pain, sponsored by GW Pharmaceuticals. Started Nov 2007; status: completed.
02
Drugs
cannabidiol
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT00530764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00530764.